(b) With the development of second- and third-generation ALK inhibitors, their synergistic effects in preclinical studies, mainly on experimental models associated with NSCLC mutations, may improve their efficacy and resistance problem. This evidence concerns the gene ALK and non-small cell lung carcinoma.